As of 2025-07-12, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -62.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 390.20 mil USD. FULC's TTM EBITDA according to its financial statements is -6.20 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.4x - 10.4x | 8.3x |
| Forward P/E multiples | 11.4x - 17.8x | 15.0x |
| Fair Price | (0.53) - (0.41) | (0.56) |
| Upside | -106.6% - -105.2% | -107.0% |
| Date | EV/EBITDA |
| 2025-07-10 | -62.99 |
| 2025-07-09 | -62.12 |
| 2025-07-08 | -61.59 |
| 2025-07-07 | -54.36 |
| 2025-07-03 | -53.49 |
| 2025-07-02 | -53.58 |
| 2025-07-01 | -52.79 |
| 2025-06-30 | -53.14 |
| 2025-06-27 | -55.06 |
| 2025-06-26 | -57.50 |
| 2025-06-25 | -55.58 |
| 2025-06-24 | -55.84 |
| 2025-06-23 | -55.67 |
| 2025-06-20 | -54.14 |
| 2025-06-18 | -48.61 |
| 2025-06-17 | -49.22 |
| 2025-06-16 | -52.44 |
| 2025-06-13 | -52.88 |
| 2025-06-12 | -52.27 |
| 2025-06-11 | -52.70 |
| 2025-06-10 | -53.31 |
| 2025-06-09 | -55.23 |
| 2025-06-06 | -56.36 |
| 2025-06-05 | -55.14 |
| 2025-06-04 | -54.45 |
| 2025-06-03 | -54.49 |
| 2025-06-02 | -53.84 |
| 2025-05-30 | -53.10 |
| 2025-05-29 | -54.80 |
| 2025-05-28 | -53.31 |
| 2025-05-27 | -48.52 |
| 2025-05-23 | -49.31 |
| 2025-05-22 | -46.52 |
| 2025-05-21 | -47.65 |
| 2025-05-20 | -49.92 |
| 2025-05-19 | -53.58 |
| 2025-05-16 | -53.14 |
| 2025-05-15 | -50.70 |
| 2025-05-14 | -42.25 |
| 2025-05-13 | -43.64 |
| 2025-05-12 | -42.68 |
| 2025-05-09 | -39.98 |
| 2025-05-08 | -40.33 |
| 2025-05-07 | -37.37 |
| 2025-05-06 | -39.81 |
| 2025-05-05 | -43.12 |
| 2025-05-02 | -42.16 |
| 2025-05-01 | -31.36 |
| 2025-04-30 | -26.74 |
| 2025-04-29 | -25.00 |